FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study(†)

BACKGROUND: A targeted agent combined with chemotherapy is the standard treatment in patients with metastatic colorectal cancer (mCRC). The present phase III study was conducted to compare two doses of bevacizumab combined with irinotecan, 5-fluorouracil/leucovorin (FOLFIRI) in the second-line setti...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ann Oncol
Egile Nagusiak: Iwamoto, S., Takahashi, T., Tamagawa, H., Nakamura, M., Munemoto, Y., Kato, T., Hata, T., Denda, T., Morita, Y., Inukai, M., Kunieda, K., Nagata, N., Kurachi, K., Ina, K., Ooshiro, M., Shimoyama, T., Baba, H., Oba, K., Sakamoto, J., Mishima, H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2015
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4478977/
https://ncbi.nlm.nih.gov/pubmed/25908603
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv197
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak